Global blood testing market is
anticipated to reach USD 62.9 billion by 2024, according to a new report by
Grand View Research, Inc. Growing adoption of testing and screening
methodologies that enhance near patient diagnosis through enhanced blood
testing that reduce diagnostic turnaround times and lower hospitals stay
durations is a major factor expected to provide lucrative growth in demand for
the market.
Federal
agencies that play a major role in regulation of genetic tests, including
Centers for Medicare and Medicaid Services, Food and Drug Administration, and
Federal Trade Commission, have also undertaken initiatives expected to further
enhance market usage of Clinical Laboratory Improvement Amendments (CLIA)
compliant tests in the market. These steps reinforce the goals set by national
governments and the medical fraternities to strengthen early diagnostic
capabilities across a number of key geographic regions.
Increasing
levels of patient awareness that have been witnessed in a number of demographic
factions across developed and developing countries alike is another notable
factor expected to drive growth. Growing prevalence of chronic diseases such as
diabetes that warrant long term disease managementis also a considerable factor
attributive of growth potential over the forecast period.
To request a
sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
- Glucose testing is estimated to be the dominant segment in 2015 owing to the high number of awareness programs carried out by various diabetes management focused associations. Presence of several local and established players in this segment that serve the market with a broad portfolio of point-of-care and portable meters for blood glucose monitoring is another factor reinforcing the dominance of this segment.
- Market revenue from of lipid panel tests is second only to blood glucose monitoring and their strong market position can be accounted for by higher incidence of cholesterol associated cardiovascular disorders as a consequence of sedentary lifestyle, need for risk analysis of cardiac diseases and screening for probability of congestive heart failure.
- Glycated hemoglobin (aka A1C) is anticipated to witness relatively faster growth among the market segments over the forecast period owing to associated higher patient convenience, faster turnaround time, higher accuracy and reliability for testing.
- North America dominated the industry in 2015, with over 40% of total revenue. Technological advancements such as the introduction of miniaturized diagnostic devices rendering rapid and accurate results that have higher market penetration in the region coupled with favorable medical insurance policies enhancing market adoption are attributive for the largest share. Favorable government initiatives and CLIA waiver on POC testing devices are also notable factors estimated drive growth.
- Asia Pacific is estimated to witnessthe fastest growth over the forecast period owing to presence of high unmet medical needs pertaining to target disease segments such as cardiovascular disorders, prostate cancer, diabetes, liver diseases, hepatotoxicity, and hyperlipedemia.
- Moreover, constantly improving healthcare expenditure in developing economies and ongoing initiatives taken by key market participants to strengthen their presence in these untapped pockets of the market is expected to drive regional market development through to 2024.
- Key players operating in this industry includeRoche Diagnostics, Abbott diagnostics, Bio-Rad Laboratories, Becton Dickinson & Company, Alere, Trinity Biotech PLC, BioMerieux SA, Nipro Diagnostics, Biomerica Inc, Siemens Healthcare, and Beckman Coulter.
- Introduction of the combination plans and other promotion programs by the clinics and laboratories which provide complete analysis of the blood are factors attributive for the projected growth in the coming years
- These entities are adopting strategies such as collaborations with hospitalsand diagnostic laboratories in order to provide online testing services. Such services include ordering a test online, carrying out the test and submission to the authorized laboratory, and retrieval of the results via e-mail so as to reduce the number of hospital visits.
See More
Reports of This Category:
About
Grand View Research:
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment